GC012F Injection infusion
Phase 1Recruiting 0 watching 0 views this week๐ค Quiet
33
Development Stage
โ
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Idiopathic Inflammatory Myopathy (IIM)
Conditions
Idiopathic Inflammatory Myopathy (IIM)
Trial Timeline
Sep 15, 2025 โ Sep 15, 2029
NCT ID
NCT07086404About GC012F Injection infusion
GC012F Injection infusion is a phase 1 stage product being developed by AstraZeneca for Idiopathic Inflammatory Myopathy (IIM). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07086404. Target conditions include Idiopathic Inflammatory Myopathy (IIM).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07086404 | Phase 1 | Recruiting |
Competing Products
20 competing products in Idiopathic Inflammatory Myopathy (IIM)